Alps Advisors Inc Jounce Therapeutics, Inc. Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $6,672 - $12,024	-2,444 Reduced 7.97%	28,212 $66,000
Q2 2022 Aug 11, 2022	SELL	$2.8 - $7.67 $62,910 - $172,329	-22,468 Reduced 42.29%	30,656 $93,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $37,105 - $52,725	-6,174 Reduced 10.41%	53,124 $361,000
Q4 2021 Feb 09, 2022	BUY	$7.11 - $9.64 $421,608 - $571,632	59,298 New	59,298 $495,000
Q4 2018 Feb 04, 2019	SELL	$2.69 - $6.71 $155,315 - $387,421	-57,738 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$6.5 - $8.37 $68,900 - $88,721	10,600 Added 22.49%	57,738 $375,000
Q2 2018 Aug 02, 2018	BUY	$7.27 - $21.88 $83,575 - $251,532	11,496 Added 32.25%	47,138 $361,000
Q2 2018 Jul 25, 2018	SELL	$7.27 - $21.88 $54,503 - $164,034	-7,497 Reduced 17.38%	35,642 $454,000
Q1 2018 May 01, 2018	BUY	$13.4 - $28.4 $100,459 - $212,914	7,497 Added 21.03%	43,139 $964,000
Q4 2017 Feb 05, 2018	BUY	$12.52 - $17.82 $49,654 - $70,674	3,966 Added 12.52%	35,642 $454,000
Q3 2017 Nov 03, 2017	BUY	$11.17 - $16.99 $353,820 - $538,175	31,676	31,676 $494,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.